Ratings Beijing Tong Ren Tang Chinese Medicine Company Limited Deutsche Boerse AG
Equities
TQR
HK0000145638
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.13 EUR | +0.89% | -.--% | -18.71% |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
Strengths
- Growth is a substantial asset for the company, as anticipated by dedicated analysts. Within the next three years, growth is estimated to reach 53% by 2026.
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- The company's attractive earnings multiples are brought to light by a P/E ratio at 12.35 for the current year.
- The company is one of the best yield companies with high dividend expectations.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- The divergence of price targets given by the various analysts who make up the consensus is relatively low, suggesting a consensus method of evaluating the company and its prospects.
- Historically, the company has been releasing figures that are above expectations.
Weaknesses
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- For the last four months, EPS estimates made by Standard & Poor's analysts have been revised downwards.
- Over the past twelve months, analysts' opinions have been revised negatively.
Ratings chart - Surperformance
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-18.71% | 102.44Cr | - | ||
+40.73% | 74TCr | C+ | ||
+32.83% | 60TCr | B | ||
-6.30% | 35TCr | C+ | ||
+15.15% | 32TCr | B- | ||
+4.05% | 28TCr | C+ | ||
+15.00% | 24TCr | B+ | ||
-5.52% | 21TCr | A+ | ||
+6.17% | 16TCr | C+ | ||
-0.45% | 16TCr | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- 3613 Stock
- TQR Stock
- Ratings Beijing Tong Ren Tang Chinese Medicine Company Limited